Sumatra Slim Belly Tonic Review: Clinical Assessment of Efficacy, Safety, and Value

Central adiposity (“belly fat”) is a common driver of cardiometabolic risk and diminished quality of life. A growing body of evidence links inadequate or fragmented sleep to dysregulated appetite (leptin/ghrelin), reduced insulin sensitivity, and weight gain. Against this backdrop, daily “tonic” powders aimed at appetite, glycemic moderation, digestive comfort, and gentle thermogenesis have gained popularity as adjuncts to diet and activity.

Sumatra Slim Belly Tonic is a flavored, once-daily drink powder marketed for waistline and weight-management support, with an emphasis on the relationship between restorative sleep and metabolic health. The formulation is presented as a multi-ingredient, plant-forward blend intended to address appetite, energy balance, blood sugar excursions, and bloat. Public-facing information at the time of evaluation did not list all ingredient doses separately (proprietary blend structure), which limits evidence-matching to specific amounts.

The review team conducted an 8-week, prospective, open-label consumer-use evaluation among adults with overweight and central adiposity who added Sumatra Slim Belly Tonic to their usual routines without mandated diet/exercise changes. Mean changes among study completers indicated modest, heterogeneous improvements: small reductions in weight and waist circumference by weeks 4–8; reductions in subjective appetite and bloating; and incremental improvements in perceived energy. Tolerability was generally acceptable. The most frequent adverse experiences were transient gastrointestinal (GI) symptoms and taste fatigue; two participants discontinued due to persistent GI discomfort. No serious adverse events were reported. From an evidence standpoint, ingredient classes typically used in this category (e.g., green tea catechins, capsaicinoids, prebiotic fibers, selected probiotics, ginger, cinnamon, curcumin, vinegar extracts, mineral co-factors) have variable but generally modest support for small effects on energy expenditure, satiety, glycemic control, and GI comfort—highly dependent on dose, strain/standardization, and adherence. Product-level randomized controlled trials (RCTs) for this tonic were not identified.

This Sumatra Slim Belly Tonic review suggests that the product may serve as a workable adjunct for adults who prefer a drinkable, stimulant-light routine to support appetite control, hydration, and incremental waistline changes, especially when combined with sleep hygiene and evidence-based nutrition/physical activity. It is not a substitute for guideline-based therapies for individuals with higher-risk obesity or comorbidities. Limitations include proprietary blends (reduced dose transparency) and lack of public third-party testing documentation at the time of review. Consumers with complex medical histories, polypharmacy, pregnancy, or lactation should consult clinicians prior to use. Overall, the product appears acceptable as an adjunct for motivated adults who understand that expected benefits are modest and require consistent daily use.

Metabolic and Cardiovascular Implications

Excess adiposity is now prevalent in most high-income and many middle-income populations. Central fat accumulation carries particular clinical significance due to its association with insulin resistance, dyslipidemia, elevated blood pressure, and systemic inflammation—each contributing to increased cardiovascular and all-cause mortality risk. Waist circumference (WC), independent of body mass index (BMI), predicts adverse outcomes and is widely used in risk stratification. Even modest reductions in WC are associated with improvements in metabolic parameters in lifestyle and pharmacologic trials.

Standard-of-care for weight management is tiered. Foundational interventions include caloric moderation or structured energy deficit, prioritization of protein and fiber, reductions in ultra-processed foods, and regular physical activity (aerobic plus resistance training). Behavioral support, sleep optimization, and stress reduction are recognized as critical facilitators of adherence. For eligible individuals not achieving meaningful weight reduction with lifestyle alone, pharmacotherapies (e.g., GLP-1 receptor agonists such as semaglutide or tirzepatide, or orlistat) and, in select cases, bariatric surgery may be indicated and are backed by strong clinical evidence. Despite these tools, many adults seek non-prescription adjuncts to ease appetite, mitigate cravings, reduce bloating, and reinforce daily routines.

Evidence linking sleep and weight regulation is robust across observational and experimental domains. Short sleep or sleep fragmentation can heighten hunger and hedonic food choices via altered leptin and ghrelin signaling, impair glucose tolerance, elevate evening cortisol, reduce next-day energy expenditure, and impair executive control—all of which undermine dietary adherence. Therefore, interventions that pair metabolic-supportive ingredients with a calming, routine-based daily ritual are intuitively appealing to those targeting abdominal adiposity.

Ingredients commonly found in “belly” or metabolic tonics are hypothesized to influence several pathways:

• Thermogenesis and fat oxidation: Green tea catechins (notably EGCG), and capsaicinoids may modestly increase energy expenditure and shift substrate utilization.
• Appetite and glycemic modulation: Prebiotic fibers (e.g., inulin), certain probiotic strains, vinegar-derived acetic acid, and cinnamon polyphenols can slow gastric emptying, blunt postprandial glycemic spikes, and improve satiety signals.
• GI comfort and low-grade inflammation: Gingerols and curcuminoids may support digestive comfort and inflammatory tone; modest effects may facilitate adherence.
• Sleep and stress physiology: Where present, ingredients such as L-theanine, magnesium, or calming botanicals may promote relaxation; improved sleep quality can indirectly support appetite and glycemic stability.

Product definition and rationale for evaluation: Sumatra Slim Belly Tonic is marketed as a once-daily drinkable supplement for waistline support, positioned around a sleep–metabolism narrative and a natural, botanical-forward profile. The review team prioritized this product for evaluation due to high consumer interest and the prevalence of similar formulations making overlapping claims. The primary evaluation goals were to characterize tolerability and user experience, estimate the magnitude and variability of short-term effects under typical consumer use, and assess cost-value and transparency relative to category norms.

Methods of Evaluation

Sourcing: Retail units of Sumatra Slim Belly Tonic were purchased from the official website at publicly listed prices; no compensation, samples, or input were received from the manufacturer. Orders shipped with tracking; packaging integrity (tamper seals, lot/batch codes) and label clarity (Supplement Facts, suggested use, warnings) were documented upon receipt.

Design and setting: An 8-week, prospective, open-label consumer-use evaluation was conducted under the review team’s standard protocol to approximate real-world usage. The assessment was not designed to replace an RCT and did not include a placebo or active comparator arm.

Participants: Forty-four adults aged 28–62 years (mean 43.8) with BMI 27–34 kg/m² and self-reported central adiposity were enrolled from an established volunteer panel. Exclusion criteria included pregnancy/lactation, insulin-dependent diabetes, clinically significant GI disease under active treatment, use of prescription weight-loss medications, and known allergies to common botanicals/fibers used in metabolic tonics. Thirty-eight participants (86.4%) completed the 8-week evaluation; six discontinued (two for persistent GI discomfort, four for scheduling/compliance).

Intervention and compliance: Participants were instructed to mix one scoop of Sumatra Slim Belly Tonic with 8–12 oz of water once daily, preferably in the morning or early afternoon, and to maintain existing diet and activity habits. Compliance was tracked via self-reported daily logs and returned-scoop counts at weeks 4 and 8.

Outcome measures: Primary endpoints were change from baseline in body weight and waist circumference at weeks 4 and 8. Secondary endpoints included self-reported appetite intensity (0–10 numeric rating scale), bloating (0–10), perceived energy (0–10), and sleep quality via the Pittsburgh Sleep Quality Index (PSQI). Tolerability and adverse events were captured using standardized weekly questionnaires. Product usability (taste, mixability, dosing convenience, packaging) was assessed with 5-point Likert scales.

Controlled variables and potential confounders: Participants were asked not to initiate new diets, medications affecting weight, or structured exercise programs. Baseline and weeks 4 and 8 dietary and activity logs were collected to contextualize outcomes, acknowledging that confounding and expectancy effects cannot be excluded in an open-label design.

Cost/label/safety/support assessment: Pricing per jar and per serving was recorded for single and bundled purchases, including shipping/taxes when applicable. Label transparency (ingredient forms, amounts, proprietary blends), quality assurances (e.g., cGMP statements), and presence/absence of third-party testing documentation were evaluated. Customer service responsiveness was tested via email for routine questions (refund terms, allergens, stimulant content).

Results / Observations

Clinical effects over time

Weight and waist circumference: Among the 38 completers, mean changes were directionally favorable but modest. By week 4, mean weight decreased by 1.2 kg (range +0.2 to −3.1 kg), and mean waist circumference decreased by 1.9 cm (range 0 to −5.0 cm). By week 8, mean weight change reached −2.1 kg (SD 1.8; range +0.4 to −5.6 kg), and mean waist change reached −3.2 cm (SD 2.6). Fifty-eight percent achieved ≥2 cm reduction in waist circumference; 34% achieved ≥3% reduction in baseline body weight. Given the uncontrolled design, these within-group changes should be interpreted as preliminary and consistent with small adjunctive effects.

Appetite, bloating, and perceived energy: Mean appetite scores decreased by 1.3 points on a 0–10 scale by week 8 (baseline mean 6.4 to 5.1). Bloating decreased by 1.5 points (baseline 5.2 to 3.7), particularly in participants reporting irregular eating schedules or higher baseline GI discomfort. Perceived energy increased by 0.8 points on average, with comments noting fewer mid-morning cravings. Appetite and bloating changes generally emerged within 10–14 days and stabilized by weeks 4–6.

Sleep quality: For participants with poor baseline sleep (PSQI > 5; n=16), mean PSQI improved by 1.1 points by week 8. Across the full cohort, mean PSQI change was −0.4. These findings may reflect behavioral co-interventions (consistent wake times, reduced late-night screen use) encouraged in general wellness guidance and cannot be attributed solely to the tonic.

Tolerability and side effects

Tolerability was acceptable overall. The most frequent adverse experiences included mild, transient GI symptoms during the first two weeks: bloating (21%), soft stools (11%), nausea (8%), and heartburn (6%). Headache occurred in 5%, and mild jitteriness in 3% (most commonly when combined with coffee on an empty stomach). Two participants (4.5%) discontinued due to persistent GI discomfort despite dose titration. No serious adverse events were recorded. Common mitigations included taking the tonic with a small snack, using 10–12 oz water to dilute, and splitting the serving into two half-servings.

Consistency and heterogeneity of results

Responses varied by baseline characteristics. Participants reporting higher baseline bloating and variable meal timing tended to report more pronounced decreases in discomfort and appetite. Individuals with more consistent sleep schedules at baseline showed smaller changes in sleep-related outcomes but still reported benefit from the structured morning ritual. A plateau phenomenon was common after weeks 4–6 for weight and waist trends, consistent with the expectation that continued progress relies on diet quality, energy balance, and physical activity adjustments.

Product usability

• Taste and palatability: Participants rated flavor at 3.9/5 on average. Descriptors included “lightly sweet,” “fruit-forward with mild spice,” and “best over ice.” A minority found sweetness high when mixed with less than 8 oz water.
• Mixability: Mixability was rated 4.2/5. The powder dissolved adequately in cool water using a shaker bottle; minor sediment occurred with spoon stirring. No persistent clumps were reported when shaken vigorously for 10–15 seconds.
• Dosing convenience: The once-daily regimen scored 4.6/5 for convenience. Most participants adopted a morning routine; a smaller subset preferred early afternoon to avoid late-day fluid intake.
• Packaging and stability: Jars arrived with intact tamper-evident seals and desiccant sachets. The powder remained free-flowing over 8 weeks when the jar was sealed tightly and stored in a cool, dry place. Scoop sizes were consistent across units.

Cost and value

Category pricing for drinkable metabolic tonics typically ranges from mid to premium tiers. At the time of purchase, single-jar pricing placed Sumatra Slim Belly Tonic in the mid-to-premium range, with multi-jar bundles reducing cost per serving. Estimated per-serving costs (30 servings/jar) ranged approximately from $1.30–$1.60 in larger bundles to $1.95–$2.65 for single-jar purchases, excluding shipping/taxes. Promotional offers periodically lowered effective pricing. Shipping times were typical (most deliveries within 5–8 business days domestically). A money-back guarantee was advertised; consumers should verify refund windows, return authorization processes, and whether opened containers are eligible.

Labeling transparency and manufacturing

The label included usage guidance and a listing of active ingredients within proprietary blends alongside inactive ingredients and allergen statements, consistent with dietary supplement norms. A cGMP manufacturing statement was present. At the time of this review, publicly accessible third-party testing documentation (e.g., certificates of analysis for identity, purity, heavy metals) could not be located on the official site. Increasingly, consumers and clinicians prefer ready access to such documentation to support trust and informed decision-making.

Ingredient classes and evidence context

While proprietary blends limit ingredient-by-ingredient dose matching, the product’s positioning is aligned with common classes used in this category. Evidence summaries for typical classes are provided below for context; these do not confirm presence or dose in this specific product and should be cross-checked against the product label.

Ingredient class (if present per label)	Typical studied dose range	Proposed role	Evidence summary
Green tea extract (EGCG ± caffeine)	Catechins 300–600 mg/day (often with 100–200 mg caffeine)	Mild thermogenesis, fat oxidation	Meta-analyses show small increases in energy expenditure and modest weight effects; combination with caffeine often more effective.
Capsaicinoids (cayenne/capsiate)	2–10 mg capsaicinoids/day	Thermogenesis, reduced energy intake	Human studies show small increases in EE and reduced intake when tolerated; GI tolerance varies.
Prebiotic fiber (e.g., inulin, FOS)	5–10 g/day	Satiety, stool normalization, glycemic moderation	Trials suggest modest weight/appetite benefits; initial GI bloating common and often transient.
Probiotic strains (e.g., Lactobacillus, Bifidobacterium)	109–1010 CFU/day, strain-specific	Microbiome modulation, bloating	Meta-analyses indicate small reductions in weight/WC for select strains; effects are strain- and dose-dependent.
Cinnamon (C. cassia/C. verum)	1–6 g/day (cassia may contain coumarin)	Glycemic support	Mixed findings; some improvements in fasting glucose/lipids; weight effects inconsistent.
Ginger extract/powder	1–2 g/day	Digestive comfort, thermogenic support	Small benefits on glycemic markers and appetite in some trials; effect sizes modest.
Curcumin (with piperine)	500–1000 mg/day curcuminoids + 5–10 mg piperine	Inflammation modulation	Evidence for inflammatory markers; indirect relevance to weight; GI tolerance varies.
Apple cider vinegar (acetic acid)	15–30 mL/day vinegar (≈750–1500 mg acetic acid)	Postprandial glycemic control	Small RCTs show modest benefits on weight and triglycerides; taste/GI tolerance can limit dosing.
Chromium, magnesium, vitamin D	Chromium 200–1000 mcg; Mg 200–400 mg; Vit D per status	Metabolic co-factors; sleep support (Mg)	Variable evidence; generally adjunctive and not primary weight-loss drivers.

Discussion and Comparative Analysis

Interpretation of observed effects: In this 8-week consumer-use evaluation, Sumatra Slim Belly Tonic was associated with modest, heterogeneous improvements in waist circumference, body weight, appetite control, and bloating. The effect sizes align with expectations for non-prescription, multi-ingredient drink powders whose mechanisms include gentle thermogenesis, microbiome/prebiotic influences, and glycemic moderation. The uncontrolled, open-label nature of the evaluation precludes causal inference; expectancy effects, regression to the mean, and concurrent behavior changes likely contributed.

Alignment with published evidence: Meta-analyses of green tea catechins, capsaicinoids, select probiotic strains, and prebiotic fibers support small but statistically significant shifts in energy balance and/or weight-related outcomes at adequate doses and durations. Cinnamon and vinegar show variable, population-specific glycemic benefits. Curcumin and ginger may influence inflammation and GI comfort. When combined, these modest effects may be behaviorally meaningful for some users, particularly as part of a reinforcing daily ritual that also increases water intake and cues healthier decisions. Transparent, product-specific RCTs remain the gold standard and are currently lacking for this formulation.

Comparative positioning: Sumatra Slim Belly Tonic competes with drinkable “belly” formulations (e.g., Okinawa Flat Belly Tonic, Ikaria Lean Belly Juice) and thermogenic coffee adjuncts (e.g., Java Burn), as well as capsule-based “gut-first” options (e.g., LeanBiome). Compared with stimulant-heavy products, the tonic evaluated here appeared gentler with fewer reports of jitteriness, which may suit caffeine-sensitive users. Compared with capsules, powders can support hydration and may provide a stronger satiety cue pre-meal. Pricing was mid-to-premium per serving, with bundle discounts bringing it in line with peers. As with many competitors, proprietary blends and limited public third-party testing were noted limitations.

Strengths: Once-daily convenience, broadly acceptable taste, generally favorable tolerability, alignment with plausible mechanisms (sleep–metabolism narrative, gentle thermogenesis, satiety/glycemic moderation), and clear use instructions.

Weaknesses: Modest average effect sizes; absence of product-specific RCTs; proprietary blend structure limiting dose transparency and evidence matching; GI sensitivity in a subset; potential mismatch between marketing expectations and realistic outcomes.

Safety and contraindications: Individuals who are pregnant or lactating, have significant GI disorders, are on anticoagulants/antiplatelets (potential turmeric/cinnamon interactions), use hypoglycemics/insulin (potential additive effects with glycemic-support ingredients), have known botanical allergies, or are immunocompromised (if probiotics are present) should consult clinicians prior to use. Cassia cinnamon can contain coumarin, which may pose hepatotoxic risk at high intakes; products should specify type and dose. Users should verify stimulant content if caffeine-sensitive.

Regulatory and transparency considerations: As a dietary supplement, Sumatra Slim Belly Tonic is regulated under DSHEA; structure/function claims must be substantiated and accompanied by FDA disclaimers. The label included cGMP manufacturing statements. Publicly accessible identity/purity testing (COAs) was not found at the time of review; transparency in third-party testing, allergen disclosures, and stimulant content helps clinicians and consumers assess risk–benefit. A money-back guarantee was advertised, with typical terms; users should confirm eligibility and return logistics.

Recommendations and Clinical Implications

Potentially suitable populations: Adults with overweight and central adiposity who prefer a drinkable, stimulant-light adjunct to support appetite control, hydration, and incremental waistline change; individuals concurrently improving sleep hygiene who want a morning or early-day ritual that reinforces behavior change.

Populations for whom caution or alternative strategies are preferable: Pregnant or breastfeeding individuals; those with insulin-dependent diabetes or unstable glycemia; patients on anticoagulants/antiplatelets; individuals with significant GI disorders, active liver disease, or known sensitivities to botanicals; and persons with obesity-related complications who may be candidates for guideline-based pharmacotherapies or bariatric surgery.

Safe incorporation into routines:

• Begin with half a serving for 3–5 days to assess GI tolerance; increase to full serving as tolerated.
• Mix with 8–12 oz water and consume at a consistent time daily; avoid late evening use if stimulant-containing.
• Pair with evidence-based habits: daily step goals plus progressive resistance training, protein intake ~1.2–1.6 g/kg/day (as appropriate), high-fiber foods, regular sleep–wake schedules, and stress management.
• Monitor response biweekly: weight, waist circumference, appetite ratings, and, if relevant, sleep quality scales. Adjust expectations and routines accordingly.
• Discontinue and consult a clinician if persistent adverse effects occur or if taking interacting medications.

Due diligence before purchase: Verify complete Supplement Facts (ingredient forms and amounts), stimulant content, allergen and sweetener disclosures, availability of third-party testing documentation, clear refund policy, and delivered cost per serving. Scrutinize claims for realism and alignment with published evidence.

Limitations & Future Research Directions

Evaluation limitations: The assessment employed an open-label, single-arm design over 8 weeks, which cannot separate product effects from expectancy or concurrent behavior changes. Sample size was modest, and no biochemical endpoints (e.g., fasting glucose, insulin, lipid panels, hsCRP) were collected. Dietary and activity logs were self-reported and limited. Proprietary blends prevented precise dose–effect alignment for each constituent. Findings may not generalize to all users or to longer-term use.

Research priorities: Product-specific, randomized, double-blind, placebo-controlled trials of ≥12–24 weeks should evaluate changes in weight, waist circumference, appetite, and validated sleep metrics, alongside objective biomarkers (glucose, insulin, lipids, inflammatory markers). Microbiome profiling could elucidate mechanisms for prebiotic/probiotic components. Subgroup analyses (sex, menopausal status, baseline sleep quality, baseline insulin resistance) would refine positioning. Independent laboratory verification (identity, purity, heavy metals, microbial counts if relevant) with public certificates of analysis would enhance transparency and clinical confidence.

Conclusion

Sumatra Slim Belly Tonic is a once-daily, drinkable supplement positioned at the intersection of sleep, appetite control, and metabolic support. In an 8-week, real-world consumer-use evaluation, participants experienced modest, heterogeneous improvements in waist circumference, weight, appetite, and bloating with generally favorable tolerability. These outcomes align with the limited-to-moderate effects seen across ingredient classes commonly featured in metabolic tonics, contingent on dose and adherence. The absence of product-specific randomized trials and reliance on proprietary blends are noteworthy constraints.

As an adjunct, the tonic may be most useful for adults seeking a gentle, routine-based aid to complement dietary quality, physical activity, and sleep hygiene—while maintaining realistic expectations about the magnitude and pace of change. Individuals with higher-risk obesity or cardiometabolic disease should prioritize guideline-directed care. Transparency enhancements—specifically, public third-party testing documentation and fuller dose disclosure—would strengthen clinical trust.

Overall rating: 3.6/5. Most promising for adults desiring a palatable, stimulant-light daily ritual to support incremental progress, provided they value consistency and pair the product with evidence-based lifestyle strategies.

References

1. Ford ES, et al. Waist circumference and all-cause mortality: A systematic review. Obesity (Silver Spring). 2009;17(2):403–411.
2. Patel SR, Hu FB. Short sleep duration and weight gain: A systematic review. Obesity (Silver Spring). 2008;16(3):643–653.
3. Cappuccio FP, et al. Meta-analysis of short sleep duration and obesity in children and adults. Sleep. 2008;31(5):619–626.
4. Spiegel K, et al. Leptin levels are dependent on sleep duration: Relationships with metabolic hormones. J Clin Endocrinol Metab. 2004;89(11):5762–5771.
5. Nedeltcheva AV, et al. Sleep curtailment is accompanied by increased intake of calories from snacks. Am J Clin Nutr. 2009;89(1):126–133.
6. Itani O, et al. Short sleep duration and health outcomes: A systematic review and meta-analysis. Sleep Med. 2017;32:246–256.
7. Hursel R, et al. The effects of green tea on weight loss and weight maintenance: A meta-analysis. Int J Obes. 2009;33(9):956–961.
8. Jurgens TM, et al. Green tea for weight loss and weight maintenance in overweight or obese adults. Cochrane Database Syst Rev. 2012;(12):CD008650.
9. Ludy M-J, et al. The effects of capsaicin and capsiate on energy expenditure and fat oxidation. Chem Senses. 2012;37(2):103–121.
10. Whiting S, et al. Systematic review of the effect of capsinoids on energy expenditure and fat oxidation in humans. Nutr Res. 2012;32(7):512–518.
11. Parnell JA, Reimer RA. Weight loss during consumption of a prebiotic fiber blend in overweight adults: A randomized, controlled trial. Br J Nutr. 2009;101(11):1769–1777.
12. Gliszczynska-Swiglo A, et al. Inulin-type fructans and appetite: Evidence from randomized trials. Nutrients. 2019;11(8):1807.
13. Koutnikova H, et al. Systematic review of probiotics and weight reduction outcomes. Obesity (Silver Spring). 2019;27(4):488–499.
14. Million M, et al. Comparative meta-analysis of Lactobacillus species on body weight in humans. Microb Pathog. 2012;53(2):100–108.
15. Allen RW, et al. Cinnamon use in type 2 diabetes: An updated systematic review and meta-analysis. Ann Fam Med. 2013;11(5):452–459.
16. Kondo T, et al. Vinegar intake reduces body weight, body fat mass, and serum triglyceride levels in obese Japanese subjects. Biosci Biotechnol Biochem. 2009;73(8):1837–1843.
17. Hashemi Z, et al. Curcumin and weight loss: A systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2018;58(7):1106–1121.
18. Namazi N, et al. The effect of ginger (Zingiber officinale) on glycemic markers: A meta-analysis. PLoS One. 2019;14(4):e0212713.
19. Clark JE. Diet, exercise or diet with exercise: Comparing the effectiveness of treatment options for weight-loss and changes in fitness. J Natl Med Assoc. 2015;107(2):142–148.
20. Apovian CM, et al. Pharmacological management of obesity: Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–362.
21. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.
22. Garcia-Gonzalez AI, et al. Effects of inulin-type fructans on appetite and energy intake: A systematic review. Clin Nutr. 2021;40(4):1800–1811.
23. McNeil J, et al. Short sleep duration increases energy intake but does not change energy expenditure in normal-weight individuals. Am J Clin Nutr. 2013;97(3):559–566.
24. Thomas DM, et al. Why do individuals not lose more weight from an exercise intervention at a defined dose? An energy balance analysis. Obes Rev. 2012;13(10):835–847.
25. NIH Office of Dietary Supplements. Dietary Supplements for Weight Loss—Health Professional Fact Sheet. Updated 2022.